Towards treating progressive multiple sclerosis. 2020

Alan Thompson, and Olga Ciccarelli
Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, London, UK. alan.thompson@ucl.ac.uk.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D004599 Electric Stimulation Therapy Application of electric current in treatment without the generation of perceptible heat. It includes electric stimulation of nerves or muscles, passage of current into the body, or use of interrupted current of low intensity to raise the detection threshold of the skin to pain. Electrotherapy,Electrical Stimulation Therapy,Interferential Current Electrotherapy,Therapeutic Electric Stimulation,Therapeutic Electrical Stimulation,Therapy, Electric Stimulation,Electric Stimulation, Therapeutic,Electrical Stimulation, Therapeutic,Electrotherapy, Interferential Current,Stimulation Therapy, Electric,Stimulation Therapy, Electrical,Stimulation, Therapeutic Electric,Stimulation, Therapeutic Electrical,Therapy, Electrical Stimulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081243 Sphingosine 1 Phosphate Receptor Modulators Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. Sphingosine Receptor Modulators
D001384 Azetidines
D001593 Benzyl Compounds Benzene derivatives that contain a benzyl group with the general formula Phenyl-CH2-R. Compounds, Benzyl
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D020528 Multiple Sclerosis, Chronic Progressive A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914) Chronic Progressive Multiple Sclerosis,Multiple Sclerosis, Progressive Relapsing,Multiple Sclerosis, Remittent Progressive,Multiple Sclerosis, Primary Progressive,Multiple Sclerosis, Secondary Progressive,Primary Progressive Multiple Sclerosis,Progressive Relapsing Multiple Sclerosis,Remittent Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis
D033581 Stem Cell Transplantation The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types. Transplantation, Stem Cell,Stem Cell Transplantations,Transplantations, Stem Cell

Related Publications

Alan Thompson, and Olga Ciccarelli
March 2014, BMJ (Clinical research ed.),
Alan Thompson, and Olga Ciccarelli
March 2011, Multiple sclerosis (Houndmills, Basingstoke, England),
Alan Thompson, and Olga Ciccarelli
January 1988, Neurologia i neurochirurgia polska,
Alan Thompson, and Olga Ciccarelli
September 2020, Annals of neurology,
Alan Thompson, and Olga Ciccarelli
June 2016, Continuum (Minneapolis, Minn.),
Alan Thompson, and Olga Ciccarelli
June 2015, Current opinion in neurology,
Alan Thompson, and Olga Ciccarelli
June 2019, Continuum (Minneapolis, Minn.),
Alan Thompson, and Olga Ciccarelli
August 2022, Continuum (Minneapolis, Minn.),
Alan Thompson, and Olga Ciccarelli
November 2009, Seminars in immunopathology,
Alan Thompson, and Olga Ciccarelli
January 2015, Multiple sclerosis international,
Copied contents to your clipboard!